Skip to content

Big Data Analysis of the Use of bIomarkers Concentration

Defining Use and Misuse of BIoMarkers Dosage and Trends in Observed Concentration Over Time: a BIg Data Analysis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03254472
Acronym
rUBIDIuM
Enrollment
585745
Registered
2017-08-18
Start date
2010-02-17
Completion date
2015-09-10
Last updated
2017-08-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biological Markers, Inappropriate Prescribing

Keywords

Biological markers, Professional practice, Big data analysis, Measured concentrations, Cardiac markers, Troponin, NTproBNP, Creatinin, INR, Hemogram, Lipid profile

Brief summary

The investigators conducted a retrospective analysis of all measured concentrations performed in a large subset of laboratories located in the French Brittany from February 2010 the 17th to August 2015 the 30th, in adults over 20 years old. The investigators are aimed at studying physicians' use and eventually misuse of biomarkers dosage and the characteristics of a broad population based on some biomarkers concentrations.

Detailed description

The rUBIDIuM study is a retrospective analysis that included all tests (but not including DNA analysis or HIV tests) performed in a large subset of laboratories located in the French Brittany from February 2010 the 17th to August 2015 the 30th. The area of study covers most of the Ille-et-Vilaine and a part of the Côtes d'Armor department in Brittany. The respective surface of these departments is 6775 and 6878 km2. All labs belong to the Biorance Laboratory group (consortium of 33 labs, Biorance Laboratoires Réunis) and are equipped with Roche Diagnostics instruments (Elecsys2010® analyzer, Roche diagnostics, Meylan, France). The main objectives are to study physicians' use and eventually misuse of biomarkers dosage and the characteristics of this broad population based on some biomarkers concentrations. For all adult patients \>20y that came to a participating lab during the study period, the investigators collected the following information: demographics data, data about the prescription (date of order, list of analysis recommended, the date of blood collection and analysis), about the prescribers and the results of the analyses. After a de-identifying process, data were aggregated. the initial analyses will 1) examine the biological tests (number, types…) ordered in a large cohort of patients, in the total population and the subgroups based on gender, age, time period, kind of lab and physicians' specialty, 2) examine the results/concentration of the analyses: blood chemistry, creatinin concentration, cardiac enzymes, natriuretic peptides, INR, lipid profile, hemogram…

Interventions

DIAGNOSTIC_TESTMeasured concentrations of biomarkers

Sponsors

Hospital Avicenne
Lead SponsorOTHER
Roche Diagnostics GmbH
CollaboratorINDUSTRY
ProBayes
CollaboratorUNKNOWN
Biorance Laboratoires Réunis
CollaboratorUNKNOWN

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All adult patients \>20 that came to a participating lab (Biorance Laboratoires Réunis) during the study period for biological measurement

Exclusion criteria

* DNA analysis, HIV test

Design outcomes

Primary

MeasureTime frameDescription
biomarker dosage prescriptionAugust 2017physicians' use and eventually misuse of biomarkers dosage

Secondary

MeasureTime frameDescription
Biomarkers dosage numbersAugust 2017Biomarkers dosage numbers before and after new treatments, released of guidelines, new tests...
Biomarkers in geriatric patientsAugust 2017biomarkers dosages and concentration in elderly/very elderly patients
Population's characteristicsAugust 2017physicians' use and eventually misuse of biomarkers dosage

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026